Windlas Biotech Limited (WINDLAS) - Total Assets
Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) holds total assets worth Rs8.14 Billion INR (≈ $88.05 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See WINDLAS total equity for net asset value and shareholders' equity analysis.
Windlas Biotech Limited - Total Assets Trend (2018–2025)
This chart illustrates how Windlas Biotech Limited's total assets have evolved over time, based on quarterly financial data. Check financial resilience of Windlas Biotech Limited to evaluate the company's liquid asset resilience ratio.
Windlas Biotech Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Windlas Biotech Limited's total assets of Rs8.14 Billion consist of 69.1% current assets and 30.9% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.1% |
| Accounts Receivable | Rs1.67 Billion | 21.9% |
| Inventory | Rs813.84 Million | 10.7% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs67.79 Million | 0.9% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Windlas Biotech Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Windlas Biotech Limited stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Windlas Biotech Limited's current assets represent 69.1% of total assets in 2025, an increase from 49.7% in 2018.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 2.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 21.9% of total assets.
Windlas Biotech Limited Competitors by Total Assets
Key competitors of Windlas Biotech Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
Windlas Biotech Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 1.91 | 1.34 |
| Quick Ratio | 1.80 | 1.61 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs2.90 Billion | Rs2.46 Billion | Rs427.40 Million |
Windlas Biotech Limited - Advanced Valuation Insights
This section examines the relationship between Windlas Biotech Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.13 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 21.4% |
| Total Assets | Rs7.60 Billion |
| Market Capitalization | $186.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Windlas Biotech Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Windlas Biotech Limited's assets grew by 21.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Windlas Biotech Limited (2018–2025)
The table below shows the annual total assets of Windlas Biotech Limited from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs7.60 Billion ≈ $82.24 Million |
+21.44% |
| 2024-03-31 | Rs6.26 Billion ≈ $67.72 Million |
+18.38% |
| 2023-03-31 | Rs5.29 Billion ≈ $57.21 Million |
+7.73% |
| 2022-03-31 | Rs4.91 Billion ≈ $53.10 Million |
+65.81% |
| 2021-03-31 | Rs2.96 Billion ≈ $32.02 Million |
-12.52% |
| 2020-03-31 | Rs3.38 Billion ≈ $36.61 Million |
+13.52% |
| 2019-03-31 | Rs2.98 Billion ≈ $32.25 Million |
+2.86% |
| 2018-03-31 | Rs2.90 Billion ≈ $31.35 Million |
-- |
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more